hotspot -WSS

hotspot

author：comprehensive 2025-10-02 00:30:08 - browse：816

Seng Cheng has been working in gene therapy for nearly as long as gene therapy has been a field. As a young scientist in the early 1990s, he was part of one of three teams racing to develop a gene therapy for cystic fibrosis, a high-profile effort that resulted in national headlines, prestigious publications, and zero patients cured.

So he’s seen the field’s highs and lows. Lately, there have been a lot of both, including at Pfizer, the company Cheng called home until this summer. The pharma brought three potentially powerful gene therapies for muscular dystrophy and hemophilia into late-stage trials but, in January, chose to abandon a large portfolio of early stage candidates that relied on the same technology: adeno-associated viruses, or AAVs, a group of small bugs that scientists spent two decades taming into a gene shipping system.

The move seemed emblematic. Across the industry, AAV companies have been struggling, either shelving programs or stopping work altogether, while investors shuttled money toward new technologies such as CRISPR and its various permutations. Longtime researchers feared promising drugs, particularly for ultra-rare diseases, might get lost in the shuffle.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： eGenesis tests gene

focus

WSS

Scientists boost immune system in aging mice by making it youthful

Steward Health Care has deal to sell doctor network to UnitedHealth

Steward Health Care has deal to sell doctor network to UnitedHealth

Readout Newsletter: Merck, J&J, and long Covid

Decaf coffee targeted by food safety group under obscure FDA rule

There's no autism epidemic. It's an autism diagnosis epidemic

focus

hotspot

explore

Psychedelics group wrestles with new pharma identity

Prior authorization will have to move faster under new Biden rule

Peter Hotez and the public health issue of online harassment

Readout LOUD podcast: mifepristone case, GLP

Affirmative action in medical school literally saved lives

Why doctors need education on FDA device approval process

United colonoscopy coverage change 'may cost lives,' doctors say

Biotech venture capitalists face new demands from investors

Tori Bowie and the unacceptable rates of Black maternal death

Prior authorization will have to move faster under new Biden rule

explore

Primary care physicians play key roles in Alzheimer's management

Readout Newsletter: Merck, Vertex, and Viking updates

Parkinson’s finding may lead to tests and, someday, treatments

There's no autism epidemic. It's an autism diagnosis epidemic

Test for long Covid? Researchers find new clue in blood samples

New brain studies show LSD's effects on the brain in full color

leisure time

focus

hotspot

entertainment